| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Calafiore Massimo | President & CEO, Director | 3451 PLANO PARKWAY, LEWISVILLE | /s/ J. Andres Cedron, attorney-in-fact | 13 Jan 2026 | 0001828602 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OFIX | Common Stock | Sale | $151,906 | -9,600 | -4.1% | $15.82 | 227,034 | 09 Jan 2026 | Direct | F1, F2, F3 |
| transaction | OFIX | Common Stock | Sale | $149,050 | -9,797 | -4.3% | $15.21 | 217,237 | 12 Jan 2026 | Direct | F1, F3, F4 |
| Id | Content |
|---|---|
| F1 | Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.57 to $16.15, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. |
| F3 | Includes 135,369 previously reported deferred stock units and an aggregate of 2,031 shares acquired under Orthofix's Stock Purchase Plan on 10/31/2025. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.02 to $15.75, inclusive. |